TheraPPI develops drugs that modulate protein interactions, with an oncology programme targeting ERK/MyD88 in the Ras-MAPK pathway. It has completed a second closing of its pre-seed round, of undisclosed size, with PULSALYS, FONGIT and new biotech-sector investors.
- Announced on
- Round
- Pre-seed
- Amount
- Amount not disclosed
- Location
- Geneva
- Sector
- Biotech & life sciences
Investors
- PULSALYS
- FONGIT
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic